drugset / Trial / NCT02364362
A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Completed
18 enrolled
Jiangsu HengRui Medicine Co., Ltd.
Shanghai Pulmonary Hospital, Shanghai, China · collab
NaSingle-groupOpen-labelTreatment
Summary
Famitinib is a tyrosin-inhibitor agent targeting at c-Kit, VEGFR2, PDGFR, VEGFR3, Flt1 and Flt3. Phase I study has shown that the toxicity is manageable. This study assessed the safety and maximum tolerated dose of continuous daily treatment with Famitinib plus docetaxel (60 mg/m\^2, every 3 weeks) in patients with Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC) to determine the recommended dose for the Phase II trial.
Timeline
- Start
- 2015-01
- Primary completion
- 2018-12
- Completion
- 2018-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famitinib | Small molecule | 15 mg | — |
| Subject | Famitinib | Small molecule | 20 mg | — |
| Subject | Famitinib | Small molecule | 25 mg | — |
| Background | Docetaxel | Small molecule | 60 mg/m2 | — |